Back to News
Market Impact: 0.35
Acadia Drug Misses Primary Goal in Alzheimer's Related Psychosis
Source: benzinga.com
Healthcare & BiotechCompany Fundamentals
Acadia Pharmaceuticals shares traded lower Thursday after the company released topline Phase 2 results from its RADIANT clinical-trial program for remlifanserin in Alzheimer's disease psychosis. The market reaction signals investor disappointment or uncertainty around the trial update, though no efficacy, safety, or financial details were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
ACAD-0.45
More News
- Jensen Huang’s $21 billion net worth in AI rout—Nvidia’s recovery will be ‘capped’ after he admitted affair with alleged Chinese spy
- Nvidia's CEO turmoil gives newly empowered Democrats fresh ammunition in pursuit of oversight
- Paraguay raids ex-president’s home: Why a bank crash brought down Pena
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Musk says Tesla will refund some Cybertruck deposits, defends decision to end production
- Weekend trading of Nvidia scandal shines light on new financial products